{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:54Z","timestamp":1787019594433,"version":"build-2736575974"},"reference-count":38,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>CD19\u2013directed chimeric antigen receptor (CAR) T cells can induce durable remissions in relapsed\/refractory large B-cell lymphomas (R\/R LBCLs), but 60% of patients do not respond or relapse. Biological mechanisms explaining lack of response are emerging, but they are largely unsuccessful in predicting disease response at the patient level. Additionally, to maximize the cost-effectiveness of CAR T-cell therapy, biomarkers able to predict response and survival before CAR T-cell manufacturing would be desirable. We performed transcriptomic and functional evaluations of leukapheresis products in 95 patients with R\/R LBCL enrolled in a prospective observational study, to identify correlates of response and survival to tisagenlecleucel and axicabtagene ciloleucel. A signature composed of 4 myeloid genes expressed by T cells isolated from leukapheresis products is able to identify patients with a very short progression-free survival (PFS), highlighting the impact of monocytes in CAR T-cell therapy response. Accordingly, response and PFS were also negatively influenced by high circulating absolute monocyte counts at the time of leukapheresis. The combined evaluation of peripheral blood monocytes at the time of leukapheresis and the 4-gene signature represents a novel tool to identify patients with R\/R LBCL at very high risk of progression after CAR T-cell therapy and could be used to plan trials evaluating CAR T cells vs other novel treatments or allogeneic CAR T cells. However, it also highlights the need to incorporate monocyte depletion strategies for better CAR T production.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012563","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:29:36Z","timestamp":1708014576000},"page":"1968-1980","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Monocytes in leukapheresis products affect the outcome of CD19\u2013targeted CAR T-cell therapy in patients with lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-1757","authenticated-orcid":false,"given":"Cristiana","family":"Carniti","sequence":"first","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2536-5766","authenticated-orcid":false,"given":"Nicole M.","family":"Caldarelli","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"2School of Medicine, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[{"name":"3Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"4Department of Molecular Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Torelli","sequence":"additional","affiliation":[{"name":"3Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"4Department of Molecular Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-1477","authenticated-orcid":false,"given":"Silva","family":"Ljevar","sequence":"additional","affiliation":[{"name":"5Biostatistics for Clinical Research Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6491-2537","authenticated-orcid":false,"given":"Sadhana","family":"Jonnalagadda","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Zanirato","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0273-1316","authenticated-orcid":false,"given":"Eugenio","family":"Fardella","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"2School of Medicine, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Stella","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"2School of Medicine, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lorenzini","sequence":"additional","affiliation":[{"name":"3Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Brich","sequence":"additional","affiliation":[{"name":"3Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Arienti","sequence":"additional","affiliation":[{"name":"6Service of Immunohematology & Transfusion Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dodero","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-0098","authenticated-orcid":false,"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-5836","authenticated-orcid":false,"given":"Martina","family":"Magni","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"1Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"2School of Medicine, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2024042313404051000_bib1","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"26","key":"2024042313404051000_bib2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024042313404051000_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024042313404051000_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024042313404051000_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"27","key":"2024042313404051000_bib6","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024042313404051000_bib7","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024042313404051000_bib8","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2024042313404051000_bib9","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024042313404051000_bib10","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"15","key":"2024042313404051000_bib11","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR T cells affects in\u00a0vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024042313404051000_bib12","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024042313404051000_bib13","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"2024042313404051000_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"27","key":"2024042313404051000_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024042313404051000_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/his.14819","article-title":"Lung carcinoid tumours: histology and Ki-67, the eternal rivalry","volume":"82","author":"Centonze","year":"2023","journal-title":"Histopathology"},{"issue":"9","key":"2024042313404051000_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.it.2021.07.002","article-title":"The tetraspan MS4A family in homeostasis, immunity, and disease","volume":"42","author":"Mattiola","year":"2021","journal-title":"Trends Immunol"},{"key":"2024042313404051000_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fimmu.2018.00454","article-title":"CD86 expression by monocytes influence an immunomodulatory profile in asymptomatic patients with chronic chagas disease","volume":"9","author":"Pinto","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"2024042313404051000_bib19","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1128\/IAI.01931-06","article-title":"Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas\u2019 disease","volume":"75","author":"Souza","year":"2007","journal-title":"Infect Immun"},{"issue":"5","key":"2024042313404051000_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/01.pas.0000157940.80538.ec","article-title":"Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte\/macrophage lineage","volume":"29","author":"Nguyen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2024042313404051000_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4132\/jptm.2015.06.01","article-title":"Cancers with higher density of tumor-associated macrophages were associated with poor survival rates","volume":"49","author":"Jung","year":"2015","journal-title":"J\u00a0Pathol Transl Med"},{"issue":"1","key":"2024042313404051000_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cas.12314","article-title":"Clinical significance of macrophage heterogeneity in human malignant tumors","volume":"105","author":"Komohara","year":"2014","journal-title":"Cancer Sci"},{"issue":"3","key":"2024042313404051000_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.clinre.2015.09.005","article-title":"Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer","volume":"40","author":"Park","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"2024042313404051000_bib24","doi-asserted-by":"crossref","first-page":"1601478","DOI":"10.1080\/2162402X.2019.1601478","article-title":"Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"issue":"10","key":"2024042313404051000_bib25","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1084\/jem.20182124","article-title":"Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell\u2013mediated tumor regression","volume":"216","author":"Etzerodt","year":"2019","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2024042313404051000_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/imm.13470","article-title":"Siglec-5 is an inhibitory immune checkpoint molecule for human T cells","volume":"166","author":"Vuchkovska","year":"2022","journal-title":"Immunology"},{"issue":"1","key":"2024042313404051000_bib27","doi-asserted-by":"crossref","first-page":"18696","DOI":"10.1038\/s41598-022-23589-9","article-title":"T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy","volume":"12","author":"Wada","year":"2022","journal-title":"Sci Rep"},{"issue":"16","key":"2024042313404051000_bib28","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010","journal-title":"Blood"},{"key":"2024042313404051000_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","article-title":"Blood monocytes: development, heterogeneity, and relationship with dendritic cells","volume":"27","author":"Auffray","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2024042313404051000_bib30","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","article-title":"Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets","volume":"118","author":"Wong","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2024042313404051000_bib31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/cyto.a.24027","article-title":"The challenge of distinguishing cell-cell complexes from singlet cells in non-imaging flow cytometry and single-cell sorting","volume":"97","author":"Burel","year":"2020","journal-title":"Cytometry A"},{"key":"2024042313404051000_bib32","doi-asserted-by":"crossref","first-page":"e46045","DOI":"10.7554\/eLife.46045","article-title":"Circulating T cell-monocyte complexes are markers of immune perturbations","volume":"8","author":"Burel","year":"2019","journal-title":"Elife"},{"issue":"3","key":"2024042313404051000_bib33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1189\/jlb.0706481","article-title":"Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation","volume":"82","author":"Mueller","year":"2007","journal-title":"J\u00a0Leukoc Biol"},{"key":"2024042313404051000_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2024042313404051000_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3324\/haematol.2013.088161","article-title":"Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era","volume":"99","author":"Tadmor","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2024042313404051000_bib36","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-019-6208-x","article-title":"Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"issue":"suppl 1","key":"2024042313404051000_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137045","article-title":"Myc expression and tumor-infiltrating T cells are associated with response in patients (Pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the Juliet Trial","volume":"136","author":"Jaeger","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2024042313404051000_bib38","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1968\/2222761\/blooda_adv-2024-012563-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1968\/2222761\/blooda_adv-2024-012563-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T09:41:01Z","timestamp":1713865261000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1968\/514980\/Monocytes-in-leukapheresis-products-affect-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012563","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}